Yang Zhao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8725478/publications.pdf

Version: 2024-02-01

50 papers	1,841 citations	27 h-index	276875 41 g-index
53	53	53	2245
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Insights into roles of METTL14 in tumors. Cell Proliferation, 2022, 55, e13168.		21
2	snoRNAs: functions and mechanisms in biological processes, and roles in tumor pathophysiology. Cell Death Discovery, 2022, 8, 259.	4.7	45
3	Box C/D snoRNA SNORD89 influences the occurrence and development of endometrial cancer through 2'-O-methylation modification of Bim. Cell Death Discovery, 2022, 8, .	4.7	13
4	Circ-NOLC1 promotes epithelial ovarian cancer tumorigenesis and progression by binding ESRP1 and modulating CDK1 and RhoA expression. Cell Death Discovery, 2021, 7, 22.	4.7	19
5	Fusion genes in gynecologic tumors: the occurrence, molecular mechanism and prospect for therapy. Cell Death and Disease, 2021, 12, 783.	6.3	5
6	Esculetin inhibits endometrial cancer proliferation and promotes apoptosis via hnRNPA1 to downregulate BCLXL and XIAP. Cancer Letters, 2021, 521, 308-321.	7.2	21
7	CircCRIM1 promotes ovarian cancer progression by working as ceRNAs of CRIM1 and targeting miR-383-5p/ZEB2 axis. Reproductive Biology and Endocrinology, 2021, 19, 176.	3.3	13
8	Research progress on the tsRNA classification, function, and application in gynecological malignant tumors. Cell Death Discovery, 2021, 7, 388.	4.7	22
9	CircRNA WHSC1 targets the miRâ€646/NPM1 pathway to promote the development of endometrial cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 6898-6907.	3.6	67
10	Circ_PUM1 promotes the development of endometrial cancer by targeting the miRâ€136/NOTCH3 pathway. Journal of Cellular and Molecular Medicine, 2020, 24, 4127-4135.	3.6	45
11	CircRhoC promotes tumorigenicity and progression in ovarian cancer by functioning as a miRâ€302e sponge to positively regulate VEGFA. Journal of Cellular and Molecular Medicine, 2019, 23, 8472-8481.	3.6	29
12	CircWHSC1 promotes ovarian cancer progression by regulating MUC1 and hTERT through sponging miR-145 and miR-1182. Journal of Experimental and Clinical Cancer Research, 2019, 38, 437.	8.6	105
13	CEMIP promotes ovarian cancer development and progression via the PI3K/AKT signaling pathway. Biomedicine and Pharmacotherapy, 2019, 114, 108787.	5.6	45
14	circ-CSPP1 promotes proliferation, invasion and migration of ovarian cancer cells by acting as a miR-1236-3p sponge. Biomedicine and Pharmacotherapy, 2019, 114, 108832.	5.6	59
15	circPUM1 Promotes Tumorigenesis and Progression of Ovarian Cancer by Sponging miR-615-5p and miR-6753-5p. Molecular Therapy - Nucleic Acids, 2019, 18, 882-892.	5.1	83
16	CircPUM1 promotes the malignant behavior of lung adenocarcinoma by regulating miR-326. Biochemical and Biophysical Research Communications, 2019, 508, 844-849.	2.1	40
17	PUM1 promotes ovarian cancer proliferation, migration and invasion. Biochemical and Biophysical Research Communications, 2018, 497, 313-318.	2.1	38
18	The role of the long nonâ€coding RNA TDRG1 in epithelial ovarian carcinoma tumorigenesis and progression through miRâ€93/RhoC pathway. Molecular Carcinogenesis, 2018, 57, 225-234.	2.7	19

#	Article	IF	CITATIONS
19	LncRNA ABHD11â€AS1 promotes the development of endometrial carcinoma by targeting cyclin D1. Journal of Cellular and Molecular Medicine, 2018, 22, 3955-3964.	3.6	43
20	LncRNA PCGEM1 Induces Ovarian Carcinoma Tumorigenesis and Progression Through RhoA Pathway. Cellular Physiology and Biochemistry, 2018, 47, 1578-1588.	1.6	38
21	IncRNA DLEU1 contributes to tumorigenesis and development of endometrial carcinoma by targeting mTOR. Molecular Carcinogenesis, 2018, 57, 1191-1200.	2.7	26
22	LncRNA TDRG1 enhances tumorigenicity in endometrial carcinoma by binding and targeting VEGF-A protein. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3013-3021.	3.8	50
23	The role of RhoC in malignant tumor invasion, metastasis and targeted therapy. Histology and Histopathology, 2018, 33, 255-260.	0.7	19
24	Circular RNAs: Characteristics, function, and role in human cancer. Histology and Histopathology, 2018, 33, 887-893.	0.7	32
25	Cancer stem cells: A new target for cancer therapy. Histology and Histopathology, 2018, 33, 1247-1252.	0.7	7
26	The role of miR-372 in ovarian carcinoma cell proliferation. Gene, 2017, 624, 14-20.	2.2	17
27	<scp>DLEU</scp> 1 contributes to ovarian carcinoma tumourigenesis and development by interacting with miRâ€490â€3p and altering <scp>CDK</scp> 1 expression. Journal of Cellular and Molecular Medicine, 2017, 21, 3055-3065.	3.6	79
28	The role of metastasisâ€associated in colon cancer 1 (MACC1) in endometrial carcinoma tumorigenesis and progression. Molecular Carcinogenesis, 2017, 56, 1361-1371.	2.7	23
29	Role of the IncRNA ABHD11-AS1 in the tumorigenesis and progression of epithelial ovarian cancer through targeted regulation of RhoC. Molecular Cancer, 2017, 16, 138.	19.2	83
30	Fascaplysin inhibit ovarian cancer cell proliferation and metastasis through inhibiting CDK4. Gene, 2017, 635, 3-8.	2.2	22
31	The role of long non-coding RNA PCA3 in epithelial ovarian carcinoma tumorigenesis and progression. Gene, 2017, 633, 42-47.	2.2	28
32	E2F-1 targets miR-519d to regulate the expression of the ras homolog gene family member C. Oncotarget, 2017, 8, 14777-14793.	1.8	13
33	MicroRNA-93 Promotes Epithelial–Mesenchymal Transition of Endometrial Carcinoma Cells. PLoS ONE, 2016, 11, e0165776.	2.5	30
34	Effects and mechanism of RhoC downregulation in suppressing ovarian cancer stem cell proliferation, drug resistance, invasion and metastasis. Oncology Reports, 2016, 36, 3267-3274.	2.6	11
35	MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α. Molecular Cancer, 2016, 15, 11.	19.2	80
36	MicroRNA-372 inhibits endometrial carcinoma development by targeting the expression of the Ras homolog gene family member C (RhoC). Oncotarget, 2016, 7, 6649-6664.	1.8	42

#	Article	IF	CITATIONS
37	The role of glycogen synthase kinase- $3\hat{1}^2$ (GSK- $3\hat{1}^2$) in endometrial carcinoma: A carcinogenesis, progression, prognosis, and target therapy marker. Oncotarget, 2016, 7, 27538-27551.	1.8	23
38	MicroRNA-186 induces sensitivity of ovarian cancer cells to paclitaxel and cisplatin by targeting ABCB1. Journal of Ovarian Research, 2015, 8, 80.	3.0	55
39	MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Drug Design, Development and Therapy, 2015, 9, 5225.	4.3	57
40	RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression. Molecular Cancer, 2015, 14, 31.	19.2	62
41	MicroRNA-490-3P targets CDK1 and inhibits ovarian epithelial carcinoma tumorigenesis and progression. Cancer Letters, 2015, 362, 122-130.	7.2	86
42	The role of the REG4 gene and its encoding product in ovarian epithelial carcinoma. BMC Cancer, 2015, 15, 471.	2.6	11
43	Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway. PLoS ONE, 2015, 10, e0125714.	2.5	30
44	Anacardic Acid Enhances the Proliferation of Human Ovarian Cancer Cells. PLoS ONE, 2014, 9, e99361.	2.5	14
45	The role of RhoC in epithelial-to-mesenchymal transition of ovarian carcinoma cells. BMC Cancer, 2014, 14, 477.	2.6	33
46	microRNA 490-3P enhances the drug-resistance of human ovarian cancer cells. Journal of Ovarian Research, 2014, 7, 84.	3.0	32
47	The role of RhoC in ovarian epithelial carcinoma: A marker for carcinogenesis, progression, prognosis, and target therapy. Gynecologic Oncology, 2013, 130, 570-578.	1.4	20
48	The Involvement of RhoA and Wnt-5a in the Tumorigenesis and Progression of Ovarian Epithelial Carcinoma. International Journal of Molecular Sciences, 2013, 14, 24187-24199.	4.1	31
49	The role of EMMPRIN expression in ovarian epithelial carcinomas. Cell Cycle, 2013, 12, 2899-2913.	2.6	24
50	RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9. Gynecologic Oncology, 2010, 116, 563-571.	1.4	31